Evaluating the Safety, Tolerability, and Disposition of Trazpiroben, a D(2)/D(3) Receptor Antagonist: Phase I Single‐ and Multiple‐Ascending Dose Studies in Healthy Japanese Participants

Trazpiroben (TAK‐906) is a peripherally selective dopamine D(2)/D(3) receptor antagonist being developed to treat chronic gastroparesis. This phase I, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose, parallel‐group study evaluated the safety, tolerability, pharmacok...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaguchi, Takayoshi, Kudou, Kentarou, Okamoto, Hiroyuki, Chen, Chunlin, Whiting, Roger, Sekino, Hisakuni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303893/
https://www.ncbi.nlm.nih.gov/pubmed/34967147
http://dx.doi.org/10.1002/cpdd.1057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303893/
https://www.ncbi.nlm.nih.gov/pubmed/34967147
http://dx.doi.org/10.1002/cpdd.1057

Ejemplares similares